Contact - Cambridge Cognition
Contact our team of experts today to answer questions provide scientific, technical, sales and product support and offer advice on your research studies.| Cambridge Cognition
Bringing Trial Activities to the Participant Lessons from the RADIAL Proof-of-Concept Trial The move toward more participant-centric clinical research has taken an important step forward. At the Clinical Pharmacology & Therapeutics journal, the first papers from the RADIAL trial, the flagship study of the Trials@Home project have now been published, offering valuable insights into how clinical research […] The post Bringing Trial Activities to the Participant – Lessons from the RADIAL P...| Cambridge Cognition
Speech Biomarkers for Alzheimer’s Disease Show Promise Across Multiple Languages The search for reliable, accessible biomarkers for early detection of cognitive decline has taken an important step forward. At AAIC 2025, our team presented data demonstrating that speech and language patterns can serve as valid digital biomarkers for Mild Cognitive Impairment (MCI) and Alzheimer’s disease […] The post Speech Analysis as an Objective Biomarker in MDD Trials Speech Biomarkers for Alzheimer...| Cambridge Cognition
Contact our team of experts today to answer questions provide scientific, technical, sales and product support and offer advice on your research studies.| Cambridge Cognition
CTAD | Posters & Presentations Hilton San Diego Bayfront, 1 Park Boulevard – San Diego, CA 92101 | 1-4th December We’re excited to announce we are attending the 18th Clinical Trials on Alzheimer’s Disease (CTAD) This year’s Clinical Trials on Alzheimer’s Disease (CTAD) conference brings together global leaders advancing research and innovation in Alzheimer’s and […] The post CTAD | Posters & Presentations appeared first on Cambridge Cognition.| Cambridge Cognition
DIS | Posters & Presentations Pfizer Innovation Research (PfIRe Lab) 1 Portland St Cambridge, MA 02139 | 5th November 09:00am – 5:30pm PST We’re excited to announce that our team will be attending the 8th Annual Digital Implementation Summit This year’s Digital Implementation Summit brings together global leaders driving the transformation of clinical development from […] The post DIS | Posters & Presentations appeared first on Cambridge Cognition.| Cambridge Cognition
Closing the Gap Speech Analysis as an Objective Biomarker in MDD Trials The development of new therapies for Central Nervous System (CNS) disorders, particularly Major Depressive Disorder (MDD), is fundamentally challenged by the subjectivity and limitations of current assessment tools. Traditional measures, which often rely on patient self-reports or clinician ratings, frequently fail to capture […]| Cambridge Cognition
CTIS | Posters & Presentations Genentech, South San Francisco, CA, USA | 15th October 08:30am – 5:30pm PST We’re excited to announce that our team will be attending the 2nd Annual Clinical Trial Innovation Summit 2025 This years Clinical Trial Innovation Summit brings together global leaders driving the future of clinical research and we’re proud […] The post CTIS | Posters & Presentations appeared first on Cambridge Cognition.| Cambridge Cognition
We’re attending ISCTM 2025 and ECNP 38th Congress 2025 to share our latest research on CNS drug development, psychiatry, and cognitive neuroscience.| Cambridge Cognition
How Picture Description Tasks Can Help Track Cognitive Health Remotely Speech as a digital biomarker in clinical research Changes in how we speak—how quickly we talk, how often we pause, and the words we choose—can be early signs of cognitive decline. People with mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) often […]| Cambridge Cognition
Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia 19 August 2025 Cambridge UK, August 19, 2025 – Cambridge Cognition (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, is […] The post Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership w...| Cambridge Cognition
Cognition in The Blood (Biomarker) How do digital cognitive assessments relate to the Blood Plasma p-Tau217 in patients with Mild Cognitive Impairment (MCI)? Our latest research explores an exciting dataset with the AI–Mind Project, who have given us the opportunity to test the associations of our cognitive assessments alongside classic paper-and-pencil tests to levels of […] The post Cognition in The Blood (Biomarker) appeared first on Cambridge Cognition.| Cambridge Cognition
When to Use Standardised Assessments—And When You Might Need to Build Your Own Alex Kaula, Senior R&D Scientist Hello, I’m Alex Kaula, Senior R&D Scientist at Cambridge Cognition. If your research involves measuring cognitive function or clinical outcomes, you’ve likely faced this question: Should I use an established, validated assessment, or create a new one […]| Cambridge Cognition
Establish a fuller understanding of patient cognitive assessment at both an individual and group level with verbal tasks.| Cambridge Cognition
